# A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

> **NCT05634369** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Pediatric Sarcoma, Refractory
- Pediatric Sarcoma, Relapsed

## Interventions

- **BIOLOGICAL:** GEM/DOX + TGFBi expanded NK cells

## Key facts

- **NCT ID:** NCT05634369
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-14
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05634369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05634369, "A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05634369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*